Clinical Trials Logo

Ototoxic Hearing Loss clinical trials

View clinical trials related to Ototoxic Hearing Loss.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05129748 Recruiting - Clinical trials for Ototoxic Hearing Loss

Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy

Start date: February 15, 2023
Phase: Phase 2
Study type: Interventional

One common side effect of cisplatin chemotherapy is ototoxicity. The drugs sodium thiosulfate and mannitol may protect against cisplatin-induced hearing loss. Specifically, sodium thiosulfate has been found to protect the cells in the inner ear, and may therefore prevent hearing loss. Mannitol can help sodium thiosulfate enter the inner ear, and ponteially increase the effectiveness of sodium thiosulfate. This study aims to assess the efficacy of sodium thiosulfate and mannitol to reduce the hearing impairment caused by cisplatin chemotherapy.

NCT ID: NCT04291209 Recruiting - Clinical trials for Ototoxic Hearing Loss

Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

Start date: February 26, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Although many intratympanic agents have been attempted, N-Acetylcysteine (NAC) appears to be the most promising and is a powerful, commonly used anti-oxidant. The goal of this prospective phase 2 randomized controlled trial is to determine the optimal dosage and effectiveness of intratympanic NAC injection in reducing hearing loss in head & neck cancer patients receiving cisplatin chemotherapy with curative intent.